Evidence map›Paper›PMID 33897439›Full record

ArticleFrontiers in pharmacology2021

Effects of Hydroxylated Mephedrone Metabolites on Monoamine Transporter Activity

Marco Niello, Daniela Cintulová, Philip Raithmayr, Marion Holy, Kathrin Jäntsch, Claire Colas, Gerhard F Ecker, Harald H Sitte, Marko D Mihovilovic

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Mephedrone and Its Metabolites: A Narrative Review.International journal of molecular sciences · 2025
    Review
  3. Article
  4. Persistent binding at dopamine transporters determines sustained psychostimulant effects.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Marco NielloInstitute of Pharmacology, Medical University, Vienna, Austria.
Daniela CintulováInstitute of Applied Synthetic Chemistry, TU Wien, Vienna, Austria.
Philip RaithmayrDepartment of Pharmaceutical Chemistry, University of Vienna, Vienna, Austria.
Marion HolyInstitute of Pharmacology, Medical University, Vienna, Austria.
Kathrin JäntschInstitute of Pharmacology, Medical University, Vienna, Austria.
Claire ColasDepartment of Pharmaceutical Chemistry, University of Vienna, Vienna, Austria.
Gerhard F EckerDepartment of Pharmaceutical Chemistry, University of Vienna, Vienna, Austria.
Harald H SitteInstitute of Pharmacology, Medical University, Vienna, Austria.
Marko D MihovilovicInstitute of Applied Synthetic Chemistry, TU Wien, Vienna, Austria.
University of Vienna · ATTU Wien · AT

Funding

Austrian Science Fund FWF W 1232
6 · The paper itself

Abstract

Mephedrone is a largely abused psychostimulant. It elicits the release of monoamines via the high affinity transporters for dopamine (DAT), norepinephrine (NET) and serotonin (SERT). Stereoselective metabolic reactions are involved in the inactivation and the elimination of its chemical structure. However, during these processes, several structures are generated and some of them have been reported to be still pharmacologically active. In this study 1) we have newly synthetized several putative mephedrone metabolites, 2) compared their activity at monoamine transporters, 3) generated quantitative structure activity relationships, and 4) exploited the chemical structure of the putative metabolites to screen a urine sample from a drug user and dissect mephedrone metabolism. We have found that most of the tested metabolites are weak inhibitors of monoamine transporters and that all of them are more potent at DAT and NET in comparison to SERT. The only exception is represented by the COOH-metabolite which shows no pharmacological activity at all three monoamine transporters. The enantioselectivity of mephedrone and its metabolites is present mainly at SERT, with only minor effects at DAT and NET being introduced when the β-keto group is reduced to an OH-group. Importantly, while at DAT the putative metabolites did not show changes in inhibitory potencies, but rather changes in their substrate/blocker profile, at SERT they showed mainly changes in inhibitory potencies. Molecular modeling suggests that the hydrophobic nature of a specific SERT subpocket may be involved in such loss of affinity. Finally, the assessment of the putative metabolites in one urine sample of mephedrone user displayed two previously uncharacterized metabolites, 4-COOH-nor-mephedrone (4-COOH-MC) and dihydro-4- nor-mephedrone (dihydro-4-MC). These results confirm and expand previous studies highlighting the importance of the stereochemistry in the pharmacodynamics of phase-1 metabolites of mephedrone, established their structure-activity relationships at DAT, NET and SERT and pave the way for a systematic dissection of mephedrone metabolic routes. Given the number of structures found having residual and modified pharmacological profiles, these findings may help in understanding the complex subjective effects of administered mephedrone. Moreover, the dissection of mephedrone metabolic routes may help in developing new therapies for treating psychostimulants acute intoxications.

Indexed as

addictioncathinonesenantiomersmephedronemetabolismmonoaminespsychostimulantstransporters

Identifiers

PMID33897439
PMCPMC8063026
OpenAlexW3154377086

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.